Table 1.
Characteristics of the patients at baseline according to CKD stage and randomized treatment assignment
| Characteristic | Baseline Stage 4 CKD (n=624) |
Baseline Stages 2/3 CKD (n=3680) |
||
|---|---|---|---|---|
| Dapagliflozin (n=293) |
Placebo (n=331) |
Dapagliflozin (n=1859) |
Placebo (n=1821) |
|
| Age (years) | 61.9 (11.8) | 62.6 (12.4) | 61.8 (12.1) | 61.8 (12.1) |
| Female sex, n (%) | 103 (35.2) | 122 (36.9) | 606 (32.6) | 594 (32.6) |
| Race, n (%) | ||||
| White | 155 (52.9) | 180 (54.4) | 969 (52.1) | 986 (54.2) |
| Black | 12 (4.1) | 11 (3.3) | 92 (5.0) | 76 (4.2) |
| Asian | 96 (32.8) | 113 (34.1) | 653 (35.1) | 605 (33.2) |
| Other | 39 (10.2) | 33 (8.2) | 145 (7.8) | 154 (8.5) |
| Body mass index (kg/m2) | 29.6 (6.7) | 29.0 (6.2) | 29.4 (5.9) | 29.8 (6.3) |
| Current smoker, n (%) | 43 (14.7) | 44 (13.3) | 240 (12.9) | 257 (14.1) |
| Blood pressure (mmHg) | ||||
| Systolic | 139.4 (19.1) | 137.1 (18.4) | 136.3 (17.2) | 137.5 (17.1) |
| Diastolic | 78.0 (10.9) | 76.4 (10.9) | 77.4 (10.6) | 77.7 (10.1) |
| eGFR (ml/min per 1.73 m2) | 26.8 (1.8) | 26.8 (1.8) | 45.8 (11.2) | 45.9 (11.2) |
| Hemoglobin (g/L) | 120.8 (16.7) | 120.0 (16.2) | 129.8 (18.0) | 129.3 (18.0) |
| Serum potassium (mEq/L) | 4.8 (0.6) | 4.8 (0.6) | 4.6 (0.5) | 4.6 (0.5) |
| Median UACR (Q1–Q3) | 1279 (642–2470) | 1212 (577–2289) | 920 (448–1841) | 911 (472–1791) |
| UACR>1000 mg/g, n (%) | 168 (57.3) | 183 (55.3) | 880 (47.3) | 848 (46.6) |
| Type 2 diabetes diagnosis, n (%) | 190 (64.9) | 211 (63.8) | 1265 (68.1) | 1240 (68.1) |
| Cardiovascular disease, n (%) | 98 (33.5) | 133 (40.2) | 715 (38.5) | 664 (36.5) |
| Baseline medication, n (%) | ||||
| ACE inhibitor/ARB | 278 (94.9) | 310 (93.7) | 1816 (97.7) | 1770 (97.2) |
| Diuretic | 154 (52.6) | 176 (53.2) | 774 (41.6) | 778 (42.7) |
| Statin | 180 (61.4) | 214 (64.7) | 1215 (65.4) | 1185 (65.1) |
Data are shown as mean (SD) unless otherwise stated. Stage 4 CKD, eGFR<30 ml/min per 1.73 m2; stages 2/3 CKD, eGFR≥30 ml/min per 1.73 m2. Q1, 25th percentile; Q3, 75th percentile; ACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.